dr. bertino on the impact of the egfr-mutated subset analysis of impower150 in nsclc
Published 4 years ago • 195 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
5:55
impower-150: egfr-mutated subset analysis
-
5:08
the impower150 regimen
-
1:39
dr. sequist on implications of the impower150 trial in advanced nonsquamous nsclc
-
1:21
dr. bertino on frontline dacomitinib in metastatic egfr nsclc
-
1:05
dr. brahmer on the impower150 trial in nsclc
-
3:18
looking at the impower data in nsclc
-
1:29
dr. vanderwalde on the clinical implications of impower150 and keynote-021
-
2:11
dr. kim discusses data from the impower150 trial in nonsquamous nsclc
-
3:05
managing the impower 150 regimen in nonsquamous mnsclc
-
4:49
impower150: quadruplet therapy for nonsquamous mnsclc
-
1:13
dr. bellmunt on challenges with immunotherapy in bladder cancer
-
2:16
impower150 update from elcc: atezolizumab and bevacizumab improve survival
-
3:51
#map2020: tumour profiling and precision oncology - don’t fear the germline
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
1:42
dr. overman on the impact of nivolumab in mcrc
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
2:13
dr. fine on gtx in inoperable pancreatic cancer
-
21:18
spotlight session: "immunotherapy/genomic implications"
-
4:45
immunotherapies and immune-related toxicities